全文获取类型
收费全文 | 132372篇 |
免费 | 9894篇 |
国内免费 | 4658篇 |
专业分类
耳鼻咽喉 | 1921篇 |
儿科学 | 2401篇 |
妇产科学 | 1797篇 |
基础医学 | 7075篇 |
口腔科学 | 2907篇 |
临床医学 | 15875篇 |
内科学 | 21930篇 |
皮肤病学 | 2313篇 |
神经病学 | 6608篇 |
特种医学 | 4170篇 |
外国民族医学 | 39篇 |
外科学 | 13859篇 |
综合类 | 18998篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5428篇 |
眼科学 | 2099篇 |
药学 | 10466篇 |
82篇 | |
中国医学 | 11182篇 |
肿瘤学 | 17749篇 |
出版年
2024年 | 337篇 |
2023年 | 2483篇 |
2022年 | 4514篇 |
2021年 | 5993篇 |
2020年 | 5611篇 |
2019年 | 5083篇 |
2018年 | 4704篇 |
2017年 | 5052篇 |
2016年 | 5495篇 |
2015年 | 5350篇 |
2014年 | 9620篇 |
2013年 | 11927篇 |
2012年 | 7765篇 |
2011年 | 8288篇 |
2010年 | 6880篇 |
2009年 | 6282篇 |
2008年 | 6181篇 |
2007年 | 6588篇 |
2006年 | 5858篇 |
2005年 | 5173篇 |
2004年 | 4179篇 |
2003年 | 3765篇 |
2002年 | 3085篇 |
2001年 | 2736篇 |
2000年 | 2251篇 |
1999年 | 1770篇 |
1998年 | 1455篇 |
1997年 | 1230篇 |
1996年 | 1038篇 |
1995年 | 915篇 |
1994年 | 727篇 |
1993年 | 552篇 |
1992年 | 499篇 |
1991年 | 461篇 |
1990年 | 400篇 |
1989年 | 343篇 |
1988年 | 335篇 |
1987年 | 290篇 |
1986年 | 225篇 |
1985年 | 256篇 |
1984年 | 225篇 |
1983年 | 169篇 |
1982年 | 168篇 |
1981年 | 163篇 |
1980年 | 131篇 |
1979年 | 121篇 |
1978年 | 68篇 |
1977年 | 45篇 |
1976年 | 49篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
W.-S. Ahn D.-J. Kim† G.-T. Chae‡ J.-M. Lee S.-M. Bae§ J.-I. Sin§ Y.-W. Kim§ S.-E. Namkoong & I. P. Lee 《International journal of gynecological cancer》2004,14(4):589-594
A mushroom extract, Agaricus blazei Murill Kyowa (ABMK), has been reported to possess antimutagenic and antitumor effects. Here, we investigate the beneficial effects of ABMK consumption on immunological status and qualities of life in cancer patients undergoing chemotherapy. One hundred cervical, ovarian, and endometrial cancer patients were treated either with carboplatin (300 mg / m(2)) plus VP16 (etoposide, 100 mg / m(2)) or with carboplatin (300 mg / m(2)) plus taxol (175 mg / m(2)) every 3 weeks for at least three cycles with or without oral consumption of ABMK. We observed that natural killer cell activity was significantly higher in ABMK-treated group (ANOVA, n = 39, P < 0.002) as compared with nontreated placebo group (n = 61). However, no significant difference in lymphokine-activated killer and monocyte activities was observed in a manner similar to the count of specific immune cell populations between ABMK-treated and nontreated groups. However, chemotherapy-associated side effects such as appetite, alopecia, emotional stability, and general weakness were all improved by ABMK treatment. Taken together, this suggests that ABMK treatment might be beneficial for gynecological cancer patients undergoing chemotherapy. 相似文献
32.
33.
Many new insights have been gained over the past 5 years into the mechanisms that regulate immune reactivity to cell and organ transplants. This new knowledge is being applied to the development of innovative experimental strategies that may soon be evaluated in the clinic. 相似文献
34.
35.
Jaw tremor can be seen as a component of various neurological disorders such as essential tremor, Parkinson's disease, dystonia, branchial myoclonus, hereditary geniospasm, task-specific tremor, and Whipple's disease, as well as in normal situations such as shivering, and subclinical physiological jaw tremor. In most of these conditions, the jaw tremor is usually associated with tremor or other abnormal involuntary movements affecting additional body parts, and its frequency is lower than 12 Hz. Schrag and colleagues reported a patient with a high-frequency idiopathic jaw tremor, and they speculated it could be related to orthostatic tremor affecting the masseter muscles. We encountered a similar patient with intermittent rapid focal jaw tremor that was successfully treated with botulinum toxin injections to the masseters. 相似文献
36.
Claudia Trenkwalder MD Heike Benes MD Ludger Grote MD Svenja Happe MD Birgit Högl MD Johannes Mathis MD Gerda M. Saletu‐Zyhlarz MD Ralf Kohnen PhD CALDIR study group 《Movement disorders》2007,22(5):696-703
We report the first large-scale double-blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated with fixed daily doses of 2 or 3 mg CAB or 200 or 300 mg levodopa for 30 weeks. Efficacy was assessed by changes in the IRLS (International RLS Severity Scale) and by time to discontinuation of treatment due to loss of efficacy or augmentation. 361 of 418 screened patients (age 58 +/- 12 years, 71% females) were randomly assigned and treated (CAB: n = 178; levodopa: n = 183) in 51 centers of four European countries. Baseline IRLS total score was 25.7 +/- 6.8. The baseline-adjusted mean change from baseline to week 6 in IRLS sum score was d = -16.1 in the CAB group and d = -9.5 in the levodopa group (d = -6.6, P < 0.0001). More patients in the levodopa group (24.0%) than in the CAB group (11.9%, P = 0.0029, log-rank test) discontinued because of loss of efficacy (14.2% vs. 7.9%, P = 0.0290) or augmentation (9.8% vs. 4.0%, P = 0.0412). Adverse events (AEs) occurred in 83.1% of the CAB group and in 77.6% of the levodopa group. In both groups, most frequent AEs were gastrointestinal symptoms (CAB: 55.6%, levodopa: 30.6%, P < 0.0001). This first large-scale active controlled study in RLS showed superior efficacy of cabergoline versus levodopa after a 30-week long-term therapy. Tolerability was found more favorable with levodopa than with cabergoline. 相似文献
37.
Péter Móricz Imre Gerlinger Jenő Solt Krisztina Somogyvári József Pytel 《European archives of oto-rhino-laryngology》2007,264(12):1441-1445
Stenosis of the hypopharyngo-oesophageal junction can be a rare complication of laryngectomy and/or partial pharyngectomy
and makes the insertion of voice prosthesis extremely difficult. This study describes the authors’ experiences gained by endoscopic
balloon-catheter dilatation of hypopharyngo-oesophageal stenoses prior to implantation of voice prostheses in four cases.
In two patients a single balloon-catheter dilatation resulted in wide enough pharyngo-oesophageal lumen on the long run. The
average prosthesis wearing-times were 6.8 months in case 1 and 4.6 months in case 2, corresponding to the published literature
data. In case 3, repeated dilatation of the pharyngo-oesophageal transition had proved to be unsuccessful despite taking every
effort with the endoscopic balloon-catheter method. Having excised the stenotic segment, reconstruction with pectoralis major
myocutaneous flap (PMMF) was indicated. Eighteen months later, a repeated restenosis was observed and a free jejunal flap
needed to be performed as a final solution. In case 4, the insertion was carried out into a previously dilated jejunal free
flap, which became gradually ischemic and stenotic since the major head-and neck procedure was carried out that resulted in
prosthesis rejection after just 1 week. The authors emphasize that correct indication of pedicled and free flaps in head and
neck reconstruction is a prerequisite from the aspect of prevention of pharyngo-oesophageal strictures. Endoscopic balloon-catheter
dilatation is a safe and established method for dilatating hypopharyngo-oesophageal stenoses of different origin. The procedure
provides maximum patient benefit with minimal trauma and morbidity; moreover, facilitates insertion of voice prostheses. However,
a single balloon-catheter dilatation cannot always result in wide enough oesophageal lumen on the long run (case 3). Insertion
of a voice prosthesis into a previously dilated ischemic jejunal segment is challenging and avoidable due to risks of complications. 相似文献
38.
Abstract The outcome of OLT for HBV-related liver disease is dependent on the prevention of allograft re-infection. Over the past decade, major advances have been made in the management of HBV transplant candidates. The advent of long-term hepatitis B immune globulin (HBIG) administration as a prophylaxis against HBV recurrence, and the introduction of new antiviral agents against HBV infection, such as lamivudine (LAM), were a major breakthrough in the management of these patients. Results of OLT for HBV infection are similar to those achieved with other indications. Pre-OLT antiviral treatment such as LAM can suppress HBV replication before OLT and thus decrease the risk of re-infection of the graft. Combination prophylaxis with LAM and HBIG after transplantation highly effectively reduces the rate of HBV re-infection, even in HBV replicative cirrhotic, patients. The optimal HBIG protocol in the LAM era is yet to be defined: dosing of HBIG, routes of administration, and possibility of stopping HBIG. Several antiviral drugs have been developed for the management of HBV infection on the graft, so outcome is currently good. 相似文献
39.
40.
LYNDA E ALBERTYN 《Journal of Medical Imaging and Radiation Oncology》1992,36(1):17-22
Both systemic and local therapy, for conditions of the breast and unrelated to it, may produce manuno-graphic changes. Some of these are characteristic, such as the pattern of scarring seen in reduction mammo-plasty. In many other instances, however, the changes produced overlap features commonly seen in malignancy. A knowledge of the timing, natural history and spectrum of these changes will aid mammographic interpretation. 相似文献